Sublingual Microcirculatory Evaluation of Extracorporeal Hemoadsorption with CytoSorb® in Abdominal Sepsis: A Case Report

Servet Duran a, Dietske Miedema b, Bülent Ergin b, Can Ince b

a Intensive Care Units, Wilhelmina Gasthuis Assen, Groningen, The Netherlands; b Department of Intensive Care Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Keywords
Microcirculation · Sepsis · Cytokemia · Hemofiltration · CytoCam-IDF · CytoSorb

Abstract
Cytokemia in septic patients is associated with microcirculatory alterations often with persistent loss of coherence between the micro- and macrocirculation, linked to organ failure and poor outcome of septic patients. Addition of a hemoadsorbant filter to an extracorporeal circuit next to conventional treatment of septic shock results in the hematological clearance of cytokines, hypothetically leading to normalization of the microcirculation and thus organ perfusion. Bedside sublingual microcirculatory assessment using handheld vital microscopy allows real-time direct visualization of the microcirculation and its response to therapy. This is demonstrated in the present case report of an 83-year-old man admitted to our intensive care unit after surgical repair of a colonic perforation for fecal soiling after a low anterior resection for a rectum carcinoma, with leakage of bowel content at the resection site. The clinical course of this patient can be described as having undergone adequate surgical treatment taking away the source of the disease, followed by optimal support including antibiotic treatment in the ICU. However, during the course of his stay in the ICU, his condition deteriorated with symptoms consistent with septic shock. Our report shows that the addition of a hemoadsorbent (CytoSorb) to the continuous renal replacement therapy circuit was associated with an improvement in the condition of our severely ill patient with abdominal sepsis. Parallel to the clinical improvement of our patient, the functional parameters of the microcirculation also showed improvement suggesting that such a noninvasive real-time evaluation of the status of the microcirculation may be a sensitive diagnostic tool to monitor the effectiveness of hemoadsorbent therapy.

Introduction
Cytokemia in septic patients is associated with alterations of the microcirculation associated with rising lactate serum levels, despite correction of the state of shock as reflected by improved systemic hemodynamic parameters. Such a condition if persistent for extended periods

Servet Duran and Dietske Miedema contributed equally to this study.

© 2021 The Author(s).
Published by S. Karger AG, Basel
of time can ultimately lead to parenchymal damage, organ failure, and adverse patient outcome.

The latest third-generation handheld vital microscope based on incident dark field imaging (CytoCam; Braedius, Huizen, The Netherlands) allows noninvasive real-time high-quality imaging of the sublingual microcirculation, offering a sensitive bedside diagnostic tool for assessment of the microcirculatory status of severely ill patients. CytoSorb® (CytoSorbents Corporation, Monmouth Junction, NJ, USA) can be placed as an additional hemoadsorber into a continuous renal replacement therapy (CRRT) circuit. The CytoSorb hemoadsorber is able to remove pro- and anti-inflammatory cytokines including other hydrophobic molecules sized between 10 and 50 kDa from the circulation. Several studies have shown the beneficial effect of CytoSorb adsorbers in short- and long-term patient outcome [1–3]. In this study, we hypothesized that the progress of CytoSorb therapy can be monitored at the level of the microcirculation [4]. Herein, we present a case report of abdominal sepsis, demonstrating the effects of treatment with a CytoSorb® hemoadsorber on the sublingual microcirculation in parallel to the clinical development.

### Table 1. Patient monitoring values

| Parameters          | T₀ baseline | T₁ (24 h) 12 h on CySo | T₂ (48 h) 36 h on CySo | T₃ (72 h) 12 h after CySo | T₄ (144 h) 84 h after CySo |
|---------------------|-------------|-------------------------|------------------------|--------------------------|---------------------------|
| Days in ICU         | 1           | 2                       | 3                      | 4                        | 7                         |
| Hb, mmol/L          | 5.6         | 5.4                     | 5.1                    | 4.8                      | 6.6                       |
| Lactate             | 9.2         | 8.6                     | 2.2                    | 1.6                      | 1.0                       |
| pH                  | 7.19        | 7.28                    | 7.38                   | 7.39                     | 7.37                      |
| HCO₃⁻, mmol/L       | 23          | 18                      | 27                     | 26                       | 26                        |
| Base excess         | −4.9        | −8.6                    | 1.2                    | 1.2                      | 0.5                       |
| PCO₂, kPa           | 8.3         | 5.0                     | 5.9                    | 5.8                      | 6                         |
| O₂, kPa             | 5.8         | 12.8                    | 10.8                   | 11.3                     | 14.5                      |
| Heart rate, bpm     | 90          | 107                     | 82                     | 111                      | 97                        |
| MAP, mm Hg          | 66          | 77                      | 80                     | 71                       | 105                       |
| Temperature, °C     | 38.5        | 38.5                    | 36.4                   | 38.0                     | 36.9                      |
| CRP                 | 433         | 345                     | 374                    | 195                      | 214                       |
| VAS score           | 99          | 56                      | 12                     | 4                        | 0                         |
| Creatinine          | 122         | 176                     | 141                    | 118                      | 102                       |
| Urea                | 15.7        | 16.3                    | 13.7                   | 11.2                     | 9.3                       |
| Urine output, mL/h  | 85          | 4.4                     | 0.8                    | 0                        | 0                         |
| Fluid balance, mL   | 1,781       | 9,564                   | 8,853                  | −2,323                   | −9,608                    |
| SOFA score          | 10          | 10                      | 10                     | 10                       | 6                         |

ICU, intensive care unit; bpm, beats per minute; HCO₃⁻, bicarbonate; MAP, mean arterial pressure; PCO₂, partial pressure of carbon dioxide; O₂, partial pressure of oxygen; VAS score, vasopressor score indicating the need for vasopressors; SOFA score, sequential organ failure assessment score (previously sepsis-related organ failure assessment score).

### Case Report

An 83-year-old man, with type 2 diabetes, hypertension, atrial fibrillation, and myocardial infarction in his past medical history, was admitted to our intensive care department after a secondary laparotomic surgery following complications from a primary low anterior resection due to a rectum carcinoma, leading to gas and fecal leakage at the resection site 2 days postoperatively. Perforations in the colon transversus were successfully closed, and a sacral abscess was evacuated/drained. The patient had aspirated during intubation and needed intensive monitoring, arriving at the intensive care unit (ICU) under sedation and hemodynamically and respiratorily stable.

Following admission to the ICU, a baseline sublingual microcirculatory measurement was made as part of an ongoing study in critically ill patients, for which the patient had been included. This opportunity provided us with an assessment of the sublingual microcirculation of this patient at baseline (t = 0 h). A sublingual microcirculatory measurement made at a time point consisted of the mean value of 3 measurements made at different sublingual locations. Several studies have shown the beneficial effect of CytoSorb adsorbers in short- and long-term patient outcome [1–3]. In this study, we hypothesized that the progress of CytoSorb therapy can be monitored at the level of the microcirculation [4]. Herein, we present a case report of abdominal sepsis, demonstrating the effects of treatment with a CytoSorb® hemoadsorber on the sublingual microcirculation in parallel to the clinical development.
mmol/L and declining renal function with a urine output of 17 mL/24 h consistent with the development of sepsis. Based on this diagnosis, it was decided to place the patient on CRRT with a CytoSorb® hemoadsorber incorporated into the circuit. After the baseline microcirculatory measurement at $t = 0$ h, we proceeded with microcirculatory measurement 24 h later and then at 36, 48, and finally at 120 h following the initial baseline measurements. In total, 2 hemoadsorbers were used, one every 24 h. The timeline of events and microcirculatory measurements are shown in Figure 1. Microcirculatory images were made in accordance with the guidelines formulated by a Task Force of the European Society for Intensive Care Medicine on sublingual microcirculatory measurements [6] and analyzed offline using dedicated software (Automated Vascular Analysis) [7]. Once the movies were downloaded from the measurement computer, the software semiautomatically recognized the vessel segments in the field of view and calculated the total vessel density (TVD) (millimeters per square millimeter) and the functional capillary density (millimeters per square millimeter). The microvascular mean flow index (MFI) is a semiquantitative index reflecting microcirculatory red blood cell flow in the field of view and was calculated as described elsewhere [6]. Twenty-four hours after being treated with CRRT plus CytoSorb®, lactate levels decreased from 9.2 mmol/L to 2.2 mmol/L, with a decreased VIS by 43%. On day 2 following the introduction of CytoSorb therapy, a 76% decrease was observed for lactate levels, and the VIS had decreased by 87%.

Fig. 1. Changes observed in microcirculatory parameters during CRRT with an add-on CytoSorb® hemoadsorbent. The average of 3 sublingual measurements was made at each time point, starting at time of entry to the ICU at $t = 0$ preceding the attachment of the CytoSorb® hemoadsorber. The key indicates the timeline of the different phases including the time at which the CytoSorb was attached and ultrafiltration and BT administered. The microcirculation parameters measured at each time point were TVD (millimeters per square millimeter; a), PVD (millimeters per square millimeter; b), PPV (% of TVD; c), and MFI (arbitrary units; d). CRRT, continuous renal replacement therapy; ICU, intensive care unit; BT, blood transfusion; TVD, total vessel density; PVD, perfused vessel density; MFI, mean flow index.
The sublingual microcirculation initially showed a reduced TVD and perfused vessel density with a reduced microcirculatory flow index (MFI). These variables together with the presence of heterogeneous plugged capillaries present in the microcirculation and high levels of lactate are consistent with the microcirculatory response associated with sepsis (see online suppl. Slide 2; for all online suppl. material, see www.karger.com/doi/10.1159/000518903; plugged vessels are highlighted) [6].

All these microcirculatory parameters improved within the first 12 h of treatment with CytoSorb® and further normalized thereafter (Fig. 1). TVD increased, and the microcirculatory flow index normalized (a value of 3 is considered normal in healthy volunteers; Fig. 1 [6]) in parallel with a reduction in lactate levels (Table 1). The microcirculatory images taken at 36 h showed a brisk flow with no plugged vessels (see online suppl. Slide 3) in parallel with an improved clinical condition (Table 1).

After 48 h of treatment with CytoSorb®, fluid ultrafiltration was initiated for restoration of fluid balance over the course of 4 days. Interestingly prior to this phase, aggressive fluid resuscitation had taken place which could be monitored as a progressive decline in TVD consistent with the dilution effects of the microcirculation [6]. During the de-escalation phase following cessation of the CytoSorb therapy, ultrafiltration was initiated and a blood transfusion administered. Monitoring the microcirculation showed that these interventions were successful in improving the diffusive capacity of the microcirculation as shown by an increase in the TVD in the final phase of the measurements (Fig. 1). The patient remained in an overall stable condition and regained consciousness and subsequently returned to the surgery ward on day 19 after admission to the ICU. After a total hospital stay of 59 days, he was discharged to a nursing facility with a normalized renal function.

Discussion

CRRT in the ICU setting together with a CytoSorb® has been shown in a retrospective study to be associated with a decreased all-cause mortality at 28 days, compared to CRRT alone [1]. Our case study shows that assessment of the sublingual microcirculation is a feasible noninvasive technique which can be used to evaluate real-time microcirculatory alterations associated with sepsis and its resolution using hemoadsorber therapy. In conclusion, our case report shows that initiation of hemoadsorption alongside standard of care improved the microcirculation and renal function alongside a decrease in lactate levels. Nevertheless, this proof of concept case study will require further larger randomized controlled clinical studies to demonstrate the use of sublingual microcirculation monitoring for evaluating the indication and success of CytoSorb® therapy.

Acknowledgments

We thank the staff of the ICU of the Wilhelmina Gasthuis Assen Hospital for the care they gave to this patient.

Statement of Ethics

Ethical approval was waived for this case report by the Board of Directors of the Wilhelmina Gasthuis Assen Hospital in accordance with local guidelines on condition that informed consent was obtained. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. The study was conducted according to the principles of the Declaration of Helsinki (version 2013, October; www.wma.net) in accordance with laws and medical research involving humans (WMO) and the requirements of Dutch law regarding human-based research.

Conflict of Interest Statement

S.D. and C.I. have received educational grants and speakers fees from CytoSorbents Europe GmbH. C.I. is Chief Scientific Officer and holds shares in Active Medical BV (Leiden, The Netherlands), a company which provides software, hardware, and educational courses related to clinical microcirculation. D.M. and B.E. have no competing interests to declare.

Funding Sources

CytoSorb hemoadsorbers were provided by CytoSorbents Europe GmbH, The Netherlands. None of the authors received any financial support for carrying out this study.

Author Contributions

S.D. provided the facilities, treated the patient with CytoSorb, and was involved in revising the manuscript. D.M. participated in the data collection and analysis of the sublingual microcirculatory measurements as well as in drafting and revising the final manuscript. B.E. was involved in the data collection and (statistical) analysis of the complete dataset and aided in the interpretation of the results. C.I. proposed the study design and gave expert insight into the interpretation of the results. He contributed to writing and approval of the final manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article and its online suppl. material files. Further enquiries can be directed to the corresponding author.
References

1 Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019 Sep 18;23(1):317.

2 Rugg C, Klose R, Hornung R, Innerhofer N, Bachler M, Schmid S, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘genetic’ matched analysis. Biomedicines. 2020;8:539.

3 Brouwer WP, Duran S, Ince C. Improved survival beyond 28 days up to 1 year after CytoSorb treatment for refractory septic shock: a propensity-weighted retrospective survival analysis. Blood Purif. 2021;50(4-5):539–45.

4 Zuccari S, Damiani E, Domizi R, Scorcella C, D’Arezzo M, Carsetti A, et al. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with CytoSorb. Blood Purif. 2020 Mar;49:107–13.

5 Koponen T, Karttunen J, Musialowicz T, Piitiläinen L, Uusaro A, Lahtinen P. Vasoinotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth. 2019 Apr;122(4):428–36.

6 Ince C, Boerma EC, Cecconi M, De Backer D, Shapiro NI, Duranteau J, et al.; Cardiovascular Dynamics Section of the ESICM. Second consensus on the assessment of sublingual microcirculation in critically ill patients: results from a task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2018 Mar;44(3):281–99.

7 Dobbe JG, Streekstra GJ, Atasever B, van Zijderveld R, Ince C. Measurement of functional microcirculatory geometry and velocity distributions using automated image analysis. Med Biol Eng Comput. 2008;46(7):659–70.